Skip to main content
Einstein logoLink to Einstein
letter
. 2020 Aug 25;18:eCE5802. doi: 10.31744/einstein_journal/2020CE5802
View full-text in Portuguese

Mesenchymal stem cells in the treatment of coronavirus-induced pneumonia (COVID-19)

Angela Mazzeo 1, Enrico Jardim Clemente Santos 2
PMCID: PMC9586424  PMID: 32876089

Dear Editor,

Stem cell therapy has been investigated by a number of basic, pre-clinical and clinical studies, and these studies have proved that stem cells are safe and effective in the treatment of many medical conditions and diseases.(1-4) A study including 10 patients with confirmed diagnosis for coronavirus 2019 (COVID-19), and pneumonia due to infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), reported significant improvement in symptoms of all patients treated with mesenchymal stem cells (MSCs) with no adverse effects. Of these patients, 7 were treated with intravenous concentration of 1x106 cells per kilogram of body weight and 3 were treated with placebo. Patients were followed-up for 14 days. Results observed included a significant reduction of chest infiltration, reduction of proinflammatory cytocines including tumor necrosis factor alpha (TNF-α), and an increase of peripheral lymphocytes rate with phenotype recovering of CD4+ T cell count and dendritic. In addition, an increase was observed of anti-inflammatory gene expression and trophic factors.(5) Although further studies including more patients are warranted, data published in the literature so far suggest that MSCs is safe and effective for treatment in patients with SARS-CoV-2 pneumonia.(5)

Chinese Clinical Trial Registry (ChiCTR2000029990).

REFERENCES

  • 1.1. Alessandrini M, Preynat-Seauve O, De Bruin K, Pepper MS. Stem cell therapy for neurological disorders. S Afr Med J. 2019;109(8b):70-7. Review. [DOI] [PubMed]; Alessandrini M, Preynat-Seauve O, De Bruin K, Pepper MS. Stem cell therapy for neurological disorders. S Afr Med J. 2019;109(8b):70–77. doi: 10.7196/SAMJ.2019.v109i8b.14009. Review. [DOI] [PubMed] [Google Scholar]
  • 2.2. Doyle EC, Wragg NM, Wilson SL. Intraarticular injection of bone marrow-derived mesenchymal stem cells enhances regeneration in knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2020 Jan 31. doi: 10.1007/s00167-020-05859-z. [Epub ahead of print] Review. [DOI] [PMC free article] [PubMed]; Doyle EC, Wragg NM, Wilson SL. Intraarticular injection of bone marrow-derived mesenchymal stem cells enhances regeneration in knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2020 Jan 31; doi: 10.1007/s00167-020-05859-z. Epub ahead of print. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.3. Hostettler KE, Gazdhar A, Khan P, Savic S, Tamo L, Lardinois D, et al. Multipotent mesenchymal stem cells in lung fibrosis. PLoS One. 2017;12(8):e0181946. Erratum in: PLoS One. 2018;13(1):e0191144. [DOI] [PMC free article] [PubMed]; Hostettler KE, Gazdhar A, Khan P, Savic S, Tamo L, Lardinois D, et al. Multipotent mesenchymal stem cells in lung fibrosis. PLoS One. 2017;12(8):e0181946. doi: 10.1371/journal.pone.0181946. Erratum in: PLoS One. 2018;13(1):e0191144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.4. Maranda EL, Rodriguez-Menocal L, Badiavas EV. Role of mesenchymal stem cells in dermal repair in burns and diabetic wounds. Curr Stem Cell Res Ther. 2017;12(1):61-70. Review. [DOI] [PubMed]; Maranda EL, Rodriguez-Menocal L, Badiavas EV. Role of mesenchymal stem cells in dermal repair in burns and diabetic wounds. Curr Stem Cell Res Ther. 2017;12(1):61–70. doi: 10.2174/1574888x11666160714115926. Review. [DOI] [PubMed] [Google Scholar]
  • 5.5. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2(-)mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216-28. [DOI] [PMC free article] [PubMed]; Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2(-)mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216–228. doi: 10.14336/AD.2020.0228. [DOI] [PMC free article] [PubMed] [Google Scholar]
Einstein (Sao Paulo). 2020 Aug 25;18:eCE5802. [Article in Portuguese]

Células-tronco mesenquimais no tratamento da pneumonia induzida pelo coronavírus (COVID-19)

Angela Mazzeo 1, Enrico Jardim Clemente Santos 2

Caro Editor,

A terapia com células-tronco tem sido alvo de intensas pesquisas básicas, pré-clínicas e clínicas, tendo sido sua segurança e eficácia comprovadas.(1-4) Em estudo realizado em dez pacientes confirmados para doença pelo coronavírus 2019 (COVID-19) acometidos por quadro de pneumonia decorrente da infecção pelo coronavírus da síndrome respiratória aguda grave 2 (SARS-CoV-2), foi observada melhora significativa nos sintomas de todos os pacientes submetidos à aplicação das células-tronco mesenquimais (CTMs) sem a detecção de efeitos adversos. Sete deles foram submetidos à administração endovenosa na concentração de 1x106 células por quilograma de peso corporal e três utilizaram placebo. Os pacientes foram acompanhados por 14 dias, tendo sido observados: significativa redução da infiltração torácica, diminuição da citocina pró-inflamatória fator de necrose tumoral-alfa (TNF-α) eaumento da taxa de linfócitos periféricos com a restauração fenotípica das células T CD4+ e dendríticas, além de um aumento da expressão gênica de fatores anti-inflamatórios e tróficos.(5) Embora sejam necessários estudos com maior número de pacientes, os dados já publicados sugerem que as CTMs podem propiciar tratamento seguro e eficaz para os pacientes que apresentam quadro de pneumonia decorrente da infecção pelo SARS-CoV-2.(5)

Chinese Clinical Trial Registry (ChiCTR2000029990).


Articles from Einstein are provided here courtesy of Instituto de Ensino e Pesquisa Albert Einstein

RESOURCES